Tearsheet

EyePoint (EYPT)

Market Price (12/23/2025): $18.85 | Market Cap: $1.3 Bil
Sector: Health Care | Industry: Biotechnology

EyePoint (EYPT)

Market Price (12/23/2025): $18.85
Market Cap: $1.3 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -14%	Trading close to highs Dist 52W High is 0.0%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -218 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -516%
1	Megatrend and thematic drivers Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more.	Weak multi-year price returns 2Y Excs Rtn is -46%	Stock price has recently run up significantly 6M Rtn6 month market price return is 128%, 12M Rtn12 month market price return is 165%
2		Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%	Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -7.4%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.1%, Rev Chg QQuarterly Revenue Change % is -91%
3			Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 69%
4			Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -498%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -504%
5			Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 146%
6			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -20%
7			Key risks EYPT key risks include [1] a heavy dependence on the clinical and regulatory success of its lead product candidate, Show more.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -14%
1	Megatrend and thematic drivers Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more.
2	Trading close to highs Dist 52W High is 0.0%
3	Weak multi-year price returns 2Y Excs Rtn is -46%
4	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%
5	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -218 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -516%
6	Stock price has recently run up significantly 6M Rtn6 month market price return is 128%, 12M Rtn12 month market price return is 165%
7	Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -7.4%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.1%, Rev Chg QQuarterly Revenue Change % is -91%
8	Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 69%
9	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -498%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -504%
10	Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 146%
11	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -20%
12	Key risks EYPT key risks include [1] a heavy dependence on the clinical and regulatory success of its lead product candidate, Show more.

Valuation, Metrics & Events

	12/23/25	2024	2023	2022	2021
Share Price CYE	$18.85	$7.45	$23.11	$3.50	$12.24
Market Cap CYE ($ Bil)	1.3	0.5	1.0	0.1	0.4
Total Debt ($ Bil)	0.0	0.0	0.0	0.0	0.0
Total Cash ($ Bil)	0.2	0.4	0.3	0.1	0.2
Enterprise Value ($ Bil)	1.1	0.5	1.0	0.1	0.4
Valuation Ratios
P/S TTM	31.2	9.7	19.5	3.2	9.5
P/EBIT TTM	-6.5	-3.2	-12.9	-1.3	-6.7
P/E TTM	-6.4	-3.2	-12.7	-1.3	-6.0
P/FCF TTM	-6.2	-3.2	-559.1	-1.9	-7.0
Sector Ratios
P/S TTM (Sector)	4.2	3.5	3.9	4.5	7.1
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4	-1.3	-2.7
P/E TTM (Sector)	-1.7	-1.5	-1.5	-1.3	-2.8
P/FCF TTM (Sector)	-1.5	-1.4	-1.4	-1.5	-3.2

	12/23/25	2024	2023
Share Price CYE	$18.85	$7.45	$23.11
Market Cap CYE ($ Bil)	1.3	0.5	1.0
Total Debt ($ Bil)	0.0	0.0	0.0
Total Cash ($ Bil)	0.2	0.4	0.3
Enterprise Value ($ Bil)	1.1	0.5	1.0
Valuation Ratios
P/S TTM	31.2	9.7	19.5
P/EBIT TTM	-6.5	-3.2	-12.9
P/E TTM	-6.4	-3.2	-12.7
P/FCF TTM	-6.2	-3.2	-559.1
Sector Ratios
P/S TTM (Sector)	4.2	3.5	3.9
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4
P/E TTM (Sector)	-1.7	-1.5	-1.5
P/FCF TTM (Sector)	-1.5	-1.4	-1.4

	EYPT	S&P 500
REVENUE GROWTH	VERY POOR
Rev LTM ($ Bil)	0.0
Rev Chg Q	-90.8%	7.3%
Rev Chg LTM	-7.4%	6.0%
Rev Chg 3Y Avg	0.1%	5.5%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.2
CFO LTM ($ Bil)	-0.2
Net Inc LTM ($ Bil)	-0.2
Op Mgn LTM	-515.7%	18.8%
CFO/Rev LTM	-498.1%	20.4%
Net Inc Mgn	-486.0%	13.1%
VALUATION	VERY HIGH
P/S	31.2	3.2
P/CFO	-6.3	15.5
P/FCF	-6.2	20.7
P/E	-6.4	23.5
STABILITY	VERY GOOD
Debt/Equity	0.02	0.21
Cash/Assets	0.81	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Number of Employees	165	12312024	Link
Number of Patents (Global)	987	10192024	Link
Total Enrollment in DURAVYU Phase 3 Wet AMD Trials (LUGANO and LUCIA)	over 900 patients	11052025	Link
Number of Pipeline Products	2	11052025	Link

Upcoming
3/04/2026	Earnings Release	Rev: - EPS: -

EYPT Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

EyePoint Pharmaceuticals (EYPT) experienced a significant stock movement of 62.9% between approximately August 31, 2025, and December 23, 2025, driven by several key developments.

1. Successful Oversubscribed Equity Financing. EyePoint completed an oversubscribed equity financing in October 2025, raising $172.5 million in gross proceeds (approximately $162 million net proceeds). This financing extended the company's cash runway into the fourth quarter of 2027 and fully funded its pivotal program for diabetic macular edema (DME).

2. Advancement in DURAVYU Phase 3 Wet AMD Trials. The company announced the completed enrollment of its Phase 3 LUGANO and LUCIA clinical trials for DURAVYU, an investigational sustained delivery treatment for wet age-related macular degeneration (wet AMD). Furthermore, in November 2025, the independent Data Safety Monitoring Committee (DSMC) provided a positive recommendation for these trials to continue as planned, noting no safety signals and strengthening confidence in DURAVYU's safety profile.

Show more EyePoint Pharmaceuticals (EYPT) experienced a significant stock movement of 62.9% between approximately August 31, 2025, and December 23, 2025, driven by several key developments.

1. Successful Oversubscribed Equity Financing. EyePoint completed an oversubscribed equity financing in October 2025, raising $172.5 million in gross proceeds (approximately $162 million net proceeds). This financing extended the company's cash runway into the fourth quarter of 2027 and fully funded its pivotal program for diabetic macular edema (DME).

2. Advancement in DURAVYU Phase 3 Wet AMD Trials. The company announced the completed enrollment of its Phase 3 LUGANO and LUCIA clinical trials for DURAVYU, an investigational sustained delivery treatment for wet age-related macular degeneration (wet AMD). Furthermore, in November 2025, the independent Data Safety Monitoring Committee (DSMC) provided a positive recommendation for these trials to continue as planned, noting no safety signals and strengthening confidence in DURAVYU's safety profile.

3. Initiation of Pivotal Phase 3 DME Program. EyePoint initiated its pivotal Phase 3 diabetic macular edema (DME) program, consisting of two identical non-inferiority trials (COMO and CAPRI), with the first patient dosing anticipated in the first quarter of 2026. DURAVYU is noted as the only tyrosine kinase inhibitor (TKI) in development for DME.

4. Preclinical Data Demonstrating Multi-Target Mechanism of Action for DURAVYU. Preclinical data presented in October 2025 at Eyecelerator at the American Academy of Ophthalmology (AAO) 2025 highlighted DURAVYU's potential as a multi-target treatment. The data showed its ability to inhibit both VEGF-mediated vascular permeability and IL-6 mediated inflammation, both of which are crucial contributors to wet AMD and DME.

5. Increased Analyst Optimism and Price Target Upgrades. Several investment analysts raised their price targets for EyePoint shares and maintained positive ratings. For example, Royal Bank of Canada lifted its price target from $28.00 to $39.00 in November 2025. The overall consensus among analysts indicated a "Moderate Buy" rating with an average target price around $30.00. Show less

Stock Movement Drivers

Fundamental Drivers

The 41.1% change in EYPT stock from 9/22/2025 to 12/22/2025 was primarily driven by a 73.5% change in the company's P/S Multiple.

	9222025	12222025	Change
Stock Price ($)	13.36	18.85	41.09%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	51.90	42.34	-18.42%
P/S Multiple	18.00	31.24	73.54%
Shares Outstanding (Mil)	69.93	70.17	-0.35%
Cumulative Contribution			41.09%

LTM = Last Twelve Months as of date shown

Market Drivers

9/22/2025 to 12/22/2025

	Return	Correlation
EYPT	41.1%
Market (SPY)	2.7%	13.6%
Sector (XLV)	13.7%	2.4%

Fundamental Drivers

The 127.7% change in EYPT stock from 6/23/2025 to 12/22/2025 was primarily driven by a 203.1% change in the company's P/S Multiple.

	6232025	12222025	Change
Stock Price ($)	8.28	18.85	127.66%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	56.04	42.34	-24.45%
P/S Multiple	10.31	31.24	203.06%
Shares Outstanding (Mil)	69.77	70.17	-0.57%
Cumulative Contribution			127.65%

LTM = Last Twelve Months as of date shown

Market Drivers

6/23/2025 to 12/22/2025

	Return	Correlation
EYPT	127.7%
Market (SPY)	14.4%	12.8%
Sector (XLV)	18.0%	15.5%

Fundamental Drivers

The 165.5% change in EYPT stock from 12/22/2024 to 12/22/2025 was primarily driven by a 269.4% change in the company's P/S Multiple.

	12222024	12222025	Change
Stock Price ($)	7.10	18.85	165.49%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	45.71	42.34	-7.38%
P/S Multiple	8.46	31.24	269.40%
Shares Outstanding (Mil)	54.45	70.17	-28.87%
Cumulative Contribution			143.37%

LTM = Last Twelve Months as of date shown

Market Drivers

12/22/2024 to 12/22/2025

	Return	Correlation
EYPT	165.5%
Market (SPY)	16.9%	27.7%
Sector (XLV)	14.5%	25.1%

Fundamental Drivers

The 552.2% change in EYPT stock from 12/23/2022 to 12/22/2025 was primarily driven by a 1127.9% change in the company's P/S Multiple.

	12232022	12222025	Change
Stock Price ($)	2.89	18.85	552.25%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	42.41	42.34	-0.18%
P/S Multiple	2.54	31.24	1127.92%
Shares Outstanding (Mil)	37.34	70.17	-87.93%
Cumulative Contribution			47.99%

LTM = Last Twelve Months as of date shown

Market Drivers

12/23/2023 to 12/22/2025

	Return	Correlation
EYPT	-16.5%
Market (SPY)	47.7%	25.1%
Sector (XLV)	18.4%	21.1%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
EYPT Return	-58%	86%	-71%	560%	-68%	134%	12%
Peers Return	�	-28%	-32%	15%	85%	48%	�
S&P 500 Return	16%	27%	-19%	24%	23%	17%	113%
Monthly Win Rates [3]
EYPT Win Rate	25%	42%	42%	50%	33%	75%
Peers Win Rate	70%	48%	45%	58%	52%	53%
S&P 500 Win Rate	58%	75%	42%	67%	75%	73%
Max Drawdowns [4]
EYPT Max Drawdown	-76%	0%	-81%	-35%	-70%	-45%
Peers Max Drawdown	�	-44%	-49%	-37%	-24%	-44%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: OCUL, REGN, KOD, APLS, TARS. See EYPT Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/22/2025 (YTD)

How Low Can It Go

Unique Key	Event	EYPT	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-87.6%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	707.0%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	257 days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-81.8%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	450.6%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	1,126 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-67.1%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	204.0%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	Not Fully Recovered days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-82.2%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	461.1%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	185 days	1,480 days

Compare to OCUL, ACSB, ALPS, APRI, CRMO

In The Past

EyePoint's stock fell -87.6% during the 2022 Inflation Shock from a high on 11/17/2021. A -87.6% loss requires a 707.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About EyePoint (EYPT)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

AI Analysis | Feedback

Here are 1-3 brief analogies for EyePoint Pharmaceuticals (EYPT):

A specialized biotech aiming to be the next Regeneron for major chronic eye diseases.
A Vertex Pharmaceuticals for advanced eye conditions.

AI Analysis | Feedback

YUTIQ: An intravitreal insert designed to deliver a sustained dose of fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
DEXYCU: An intracameral suspension of dexamethasone indicated for the treatment of post-operative inflammation following ocular surgery.

AI Analysis | Feedback

EyePoint Pharmaceuticals (EYPT) sells primarily to other companies, specifically pharmaceutical wholesalers, which then distribute the products to pharmacies, hospitals, clinics, and other healthcare providers.

The company's major customers, accounting for approximately 99% of its gross product sales, are:

AmerisourceBergen (Symbol: ABC)
McKesson Corporation (Symbol: MCK)
Cardinal Health, Inc. (Symbol: CAH)

AI Analysis | Feedback

EyePoint (EYPT) relies on the following major suppliers:

Alcon Inc. (ALC)
Cambrex Corporation
LTS Lohmann Therapie-Systeme AG

AI Analysis | Feedback

Jay S. Duker, M.D. President & CEO and Board Director

Dr. Duker joined EyePoint in 2020 and became President & CEO in July 2023. He previously served EyePoint as President and Chief Operating Officer, and as Chief Strategic Scientific Officer. With over 30 years in the field of ophthalmology, Dr. Duker has held roles in clinical research, business, and academic settings. He also served on EyePoint's Board of Directors from 2016-2020 before re-appointment in July 2023.

George O. Elston Executive Vice President, Chief Financial Officer

Mr. Elston joined EyePoint in 2019 as CFO & Head of Corporate Development, and was promoted to Executive Vice President & CFO in October 2023. Prior to EyePoint, he was Chief Financial Officer & Head of Corporate Development at Enzyvant Therapeutics, where he contributed to building the pre-commercial rare disease firm, leading to its acquisition. He also served as President and Chief Executive Officer at 2X Oncology, Inc., advancing the company from a spin-out into a multiprogram, clinical-stage organization. His career began in public accounting at PriceWaterhouseCoopers.

Ramiro Ribeiro, M.D., Ph.D. Chief Medical Officer

Dr. Ribeiro is a retinal specialist and leads EyePoint's Clinical Development, Clinical Operations, and Medical Safety teams. He brings over 15 years of experience from clinical practice, academia, and the pharmaceutical industry.

Ron Honig Esq. Chief Legal Officer & Company Secretary

Mr. Honig has served as Chief Legal Officer and Company Secretary since 2018.

Scott Jones, M.A. Chief Commercial Officer

Mr. Jones joined EyePoint in 2019. Prior to this, he was Chief Commercial Officer and Vice President, Business Development, at Notal Vision, where he developed the organization's commercial and growth strategy.

AI Analysis | Feedback

The key risks to EyePoint Pharmaceuticals (EYPT) include:

Clinical Trial and Regulatory Approval Risks: The success of EyePoint Pharmaceuticals is heavily dependent on the outcomes of its clinical trials and the ability to secure regulatory approvals for its product candidates, particularly DURAVYU™ (EYP-1901). The development and approval of new drugs are subject to stringent regulatory requirements, which are time-consuming and costly. The inherent uncertainties of clinical trial results mean that delays, terminations, or even preliminary data differing from actual results can significantly harm the company's business, financial condition, and prospects.
Financial Risks and Need for Additional Capital: EyePoint Pharmaceuticals is currently unprofitable, with persistent losses and rising operating expenses. The company will likely require additional capital to fund its ongoing operations and product development. Should EyePoint be unable to secure sufficient funding, it may be forced to scale back its operations and adjust its business strategy, which could threaten its financial stability if key regulatory or commercial milestones are not met as projected.
Market Dependence and Competition: EyePoint Pharmaceuticals relies significantly on the performance of its existing commercial products, YUTIQ and DEXYCU. The ophthalmology market is highly competitive, with numerous companies vying for market share. Even with successful clinical development, the crowded nature of this market could limit the commercial potential and market penetration of EyePoint's pipeline products.

AI Analysis | Feedback

A clear emerging threat for EyePoint Pharmaceuticals is the advancement and potential commercialization of gene therapies for wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

Companies such as Regenxbio (with RGX-314, licensed to AbbVie as ABBV-805) and Adverum Biotechnologies (with ADVM-022) are developing gene therapies that aim to provide continuous production of anti-VEGF proteins from a one-time subretinal or intravitreal injection. If successful in late-stage clinical trials and approved, these therapies could fundamentally disrupt the market for wet AMD, DME, and RVO treatments by potentially offering years of efficacy from a single administration, thereby reducing or eliminating the need for periodic anti-VEGF injections or sustained-release implants like EyePoint's pipeline product EYP-1901.

This emerging technology represents a potential paradigm shift, moving beyond frequent injections or even multi-month implants towards a long-term, possibly curative, solution, which could significantly undermine the value proposition of EyePoint's current and future sustained-release platforms for these indications.

AI Analysis | Feedback

EyePoint Pharmaceuticals' Addressable Markets

EyePoint Pharmaceuticals (NASDAQ: EYPT) focuses on developing and commercializing innovative ophthalmic products utilizing sustained-release drug delivery technologies for serious retinal diseases. Its main products and pipeline candidates target significant addressable markets.

YUTIQ® (fluocinolone acetonide intravitreal implant)

YUTIQ is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The total uveitis market size in the seven major markets (7MM) was approximately USD 1,468.66 million in 2022, with the U.S. accounting for USD 759.03 million of this market.

DEXYCU® (dexamethasone intraocular suspension)

DEXYCU is an FDA-approved, single-dose, sustained-release intracameral steroid for the treatment of postoperative inflammation following cataract surgery. While a specific total market size for "postoperative inflammation following cataract surgery" isn't explicitly stated as a single figure, Medicare covers 75% to 80% of all cataract surgeries in the U.S. DEXYCU's wholesale acquisition cost (WAC) is $595 per injection in the U.S.

EYP-1901 (DURAVYU™)

EYP-1901 (conditionally accepted proprietary name DURAVYU™) is EyePoint's lead pipeline program, an investigational sustained intravitreal treatment in Phase 2 clinical trials. It is being developed for:

Wet Age-related Macular Degeneration (wet AMD): This is the leading cause of vision loss among people aged 50 and older in the U.S. The number of people with AMD in the U.S. is expected to more than double from 2.07 million in 2010 to 5.44 million by 2050. The Age-related Macular Degeneration (AMD) segment is expected to dominate the overall ophthalmology drug market by indication. The global ophthalmic drugs market, which includes treatments for AMD, was estimated at USD 38.20 billion in 2024 and is projected to reach USD 62.08 billion by 2030, with North America holding the largest share (42.7% in 2024).
Non-proliferative Diabetic Retinopathy (NPDR): This is a largely untreated disease due to limitations of available therapies.
Diabetic Macular Edema (DME): The global ophthalmic disease therapeutics market, which includes treatments for retinal disorders like DME, was valued at USD 35.54 billion in 2024 and is projected to reach USD 60.56 billion by 2033, growing at a CAGR of 6.1% (2026–2033). The Centers for Disease Control and Prevention (CDC) predicts that by 2050, 14.6 million Americans will have diabetic retinopathy, up from 7.7 million in 2010.

The overall global ophthalmic drug market is projected to reach USD 26.28 billion by 2030 from USD 19.52 billion in 2025, with a CAGR of 6.1% from 2025 to 2030. Another estimate places the global ophthalmic drug market size at USD 38.20 billion in 2024, projected to reach USD 62.08 billion by 2030, growing at a CAGR of 8.5% from 2025 to 2030. North America holds a significant share of this market, accounting for 61.1% of revenue in 2024 for ophthalmology drugs.

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for EyePoint (EYPT)

Over the next 2-3 years, EyePoint Pharmaceuticals (EYPT) anticipates several key drivers for future revenue growth, primarily centered around the successful development and commercialization of its lead product candidate, DURAVYU™.

Commercialization of DURAVYU for Wet Age-related Macular Degeneration (wet AMD): EyePoint's primary revenue driver is expected to be the successful launch and market penetration of DURAVYU for wet AMD. The company has completed enrollment for its Phase 3 LUGANO and LUCIA trials in the second half of 2025, with top-line data anticipated in mid-2026. Analysts project significant revenue potential for DURAVYU, highlighting its value as a durable, long-acting (every 6 months) treatment in a multi-billion dollar market.
Expansion into Diabetic Macular Edema (DME) with DURAVYU: Building on the wet AMD program, EyePoint is advancing its pivotal Phase 3 program for DME, with the first patient dosing targeted for the first quarter of 2026. The company has aligned with the FDA on a non-inferiority trial design, which it believes is clinically rigorous and derisked. Positive Phase 2 VERONA trial results for DURAVYU in DME, reported in Q4 2024, further support this pipeline expansion.
DURAVYU's Differentiated Profile and Sustained Delivery Technology: EyePoint's proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery is expected to be a significant competitive advantage. This technology, which enables long-acting treatment, offers the potential for a first-to-market advantage in sustained release therapies for retinal diseases and is anticipated to drive strong physician adoption by reducing the frequency of eye injections.
Multi-Mechanism of Action and Broader Pipeline Opportunities: New preclinical data indicates that vorolanib, the active drug in DURAVYU, uniquely inhibits both VEGF-mediated vascular permeability and interleukin-6 (IL-6) mediated inflammation. This multi-mechanism of action could potentially lead to label expansion or new indications, further broadening DURAVYU's market potential. Beyond DURAVYU, EyePoint's pipeline is noted to represent multibillion-dollar product opportunities, suggesting ongoing investment in research and development for future growth.

AI Analysis | Feedback

Share Repurchases

In December 2022, EyePoint Pharmaceuticals entered into a private stock repurchase for three million shares of common stock at $1.60 per share from BML Investment Partners, L.P..
In 2022, the company purchased 558,976 shares of common stock at an average price of $5.01 per share under a stock repurchase plan established in June 2021, which was terminated in April 2022.

Share Issuance

In October 2025, EyePoint Pharmaceuticals completed an underwritten public offering with gross proceeds of $172.5 million by selling 11,000,000 shares of common stock and pre-funded warrants to acquire 1,500,000 shares, including the underwriters' full exercise of their option to purchase an additional 1,875,000 shares. The net proceeds were $162 million.
In November 2021, EyePoint announced an underwritten public offering with expected gross proceeds of approximately $100.3 million, with an option for underwriters to purchase an additional $15.0 million in shares.
In February 2021, the company sold 10,465,000 shares of common stock in an underwritten public offering for approximately $115.1 million in gross proceeds.
Under an at-the-market (ATM) facility, EyePoint sold 721,274 shares for approximately $7.7 million in gross proceeds after June 30, 2023, and 1,299,506 shares for approximately $12.2 million in gross proceeds during July 2024.
In January 2024, SWK exercised warrants resulting in a net share issuance of 25,666 shares, and in April 2024, 2,181,818 pre-funded warrants were exercised, leading to a net issuance of 2,180,776 shares of common stock.

Inbound Investments

In December 2020, Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company, made a $15.7 million equity investment in EyePoint Pharmaceuticals, purchasing approximately 3.01 million shares of common stock.

Better Bets than EyePoint (EYPT)

Apple

NVDA (2.2%)

NVIDIA

		Best Bets In Health Care Sector
	EYPT	RPRX	HALO	DOCS	CPRX	HRMY	LGND	ISRG	GMED	MD	HIMS
What You Pay
P/E	-6.4	21.9	13.4	33.4	13.7	12.0	79.8	75.3	28.4	11.5	59.3
P/EBIT	-6.5	10.6	10.5	34.2	11.5	9.1	58.0	73.4	27.7	7.7	69.0
What You Get
Rev Chg Q	-90.8%	7.9%	22.1%	23.2%	15.3%	28.7%	122.8%	22.9%	22.9%	-3.6%	49.2%
Rev Chg LTM	-7.4%	3.7%	31.2%	20.2%	25.6%	21.1%	64.8%	22.2%	11.7%	-4.2%	78.0%
Rev Chg 3Y Avg	0.1%	1.5%	29.0%	17.4%	46.5%	27.4%	16.0%	16.3%	45.6%	-0.5%	71.0%
FCF/Rev 3Y Avg	-247.0%	115.2%	45.0%	42.7%	34.2%	33.2%	23.9%	16.5%	14.3%	8.9%	6.9%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	EyePoint Earnings Notes
2	Would You Still Hold EyePoint Stock If It Fell 30%?	Return
3	EyePoint Pharmaceuticals (EYPT) Stock: 48% of days in last 3 months had 1% or greater fluctuation
4	Day 7 of Gains Streak for EyePoint Pharmaceuticals Stock with 12% Return (vs. -61% YTD) [10/8/2024]	Notification
5	Day 5 of Gains Streak for EyePoint Pharmaceuticals Stock with 12% Return (vs. -61% YTD) [10/4/2024]	Notification
6	EyePoint Pharmaceuticals vs. S&P500 Correlation	Correlation
7	EyePoint Pharmaceuticals Price Volatility	Volatility
8	Day 5 of Gains Streak for EyePoint Pharmaceuticals Stock with 11% Return (vs. -3.5% YTD) [4/11/2024]	Notification
9	EyePoint Pharmaceuticals Market Price	Market Price
10	Day 5 of Loss Streak for EyePoint Pharmaceuticals Stock with -24% Return (vs. 138% YTD) [9/21/2023]	Notification

	Title
0	ARTICLES

Trade Ideas

Select ideas related to EYPT. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	21.0%	21.0%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-8.8%	-8.8%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	11.5%	11.5%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.7%	2.7%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	13.8%	13.8%	-5.1%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ADEA	Adeia	1.8	30.5%	21.0%
AAOI	Applied Optoelectronics	2.5	24.8%	6.1%
QBTS	D-Wave Quantum	11.0	20.0%	283.2%
ZBIO	Zenas BioPharma	1.8	17.1%	416.8%
UNF	UniFirst	3.6	16.1%	16.4%
FLY	Firefly Aerospace	4.0	16.0%
UAMY	United States Antimony	0.7	16.0%	215.8%
RZLT	Rezolute	0.2	15.8%	-58.2%
RCAT	Red Cat	0.8	14.5%	-28.2%
KURA	Kura Oncology	1.0	14.5%	29.4%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
TPL	Texas Pacific Land	7.0	-66.3%	-72.5%
EWTX	Edgewise Therapeutics	2.2	-18.0%	-21.6%
DJT	Trump Media & Technology	4.0	-10.4%	-57.7%
AVO	Mission Produce	0.8	-9.7%	-17.0%
GTN-A	Gray Media	1.0	-8.0%	43.1%
ANGX	Angel Studios	0.8	-8.0%
DDS	Dillard's	9.6	-7.7%	48.3%
NKTR	Nektar Therapeutics	0.6	-7.2%	211.7%
MPLT	MapLight Therapeutics	0.8	-6.7%
TLRY	Tilray Brands	11.0	-6.6%	-21.7%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
LUNR	Intuitive Machines	2.0	50.1%	-8.1%
FBYD	Falcons Beyond Global	0.7	46.4%	129.2%
TE	T1 Energy	1.1	44.3%
HUT	Hut 8	5.3	42.2%	145.9%
FLY	Firefly Aerospace	4.0	40.5%
RKLB	Rocket Lab	39.9	40.0%	204.5%
DJT	Trump Media & Technology	4.0	37.8%	-57.7%
QBTS	D-Wave Quantum	11.0	35.6%	283.2%
EEX	Emerald	0.9	34.2%	-0.1%
AAOI	Applied Optoelectronics	2.5	30.8%	6.1%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
NOW	ServiceNow	32.5	-79.5%	-26.1%
TPL	Texas Pacific Land	7.0	-63.9%	-72.5%
LW	Lamb Weston	6.0	-28.0%	-34.3%
OLMA	Olema Pharmaceuticals	2.4	-21.4%	383.4%
FDMT	4D Molecular Therapeutics	0.5	-20.5%	56.4%
NKTR	Nektar Therapeutics	0.6	-18.4%	211.7%
INSP	Inspire Medical Systems	2.9	-17.9%	-47.2%
PLAY	Dave & Buster's Entertainment	0.6	-17.9%	-45.0%
NKE	Nike	84.5	-15.6%	-22.6%
HPP	Hudson Pacific Properties	4.6	-14.9%	-51.6%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
TE	T1 Energy	1.1	168.4%
WVE	WAVE Life Sciences	2.9	166.0%	45.3%
LUNR	Intuitive Machines	2.0	107.3%	-8.1%
AAOI	Applied Optoelectronics	2.5	100.6%	6.1%
RKLB	Rocket Lab	39.9	96.4%	204.5%
VERA	Vera Therapeutics	3.4	93.0%	27.2%
ANF	Abercrombie & Fitch	5.9	83.9%	-16.6%
PL	Planet Labs PBC	6.3	83.4%	409.9%
ARWR	Arrowhead Pharmaceuticals	9.6	81.1%	267.0%
FTRE	Fortrea	1.6	76.2%	-5.1%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
RZLT	Rezolute	0.2	-78.8%	-58.2%
TPL	Texas Pacific Land	7.0	-65.7%	-72.5%
JANX	Janux Therapeutics	0.9	-50.7%	-73.7%
FRMI	Fermi	6.2	-42.4%
LENZ	LENZ Therapeutics	0.5	-36.4%	-39.0%
GOGO	Gogo	0.6	-30.3%	-41.9%
UP	Wheels Up Experience	0.4	-27.4%	-62.1%
ACLX	Arcellx	3.7	-27.2%	-15.0%
ORIC	ORIC Pharmaceuticals	0.7	-26.8%	4.1%
KOS	Kosmos Energy	0.5	-26.5%	-71.8%

Peer Comparisons for EyePoint

Peers to compare with:

Financials

	EYPT	OCUL	REGN	KOD	APLS	TARS	Median
Name	EyePoint	Ocular T.	Regenero.	Kodiak S.	Apellis .	Tarsus P.
Mkt Price	18.85	12.96	779.36	28.61	25.40	81.98	27.00
Mkt Cap	1.3	2.4	80.7	1.5	3.2	3.5	2.8
Rev LTM	42	56	14,248	0	1,016	366	211
Op Inc LTM	-218	-251	3,807	-223	80	-87	-153
FCF LTM	-214	-199	3,881	-127	79	-63	-95
FCF 3Y Avg	-107	-130	3,853	-157	-255	-86	-119
CFO LTM	-211	-190	5,071	-127	79	-54	-90
CFO 3Y Avg	-104	-124	4,848	-141	-255	-81	-114

Growth & Margins

	EYPT	OCUL	REGN	KOD	APLS	TARS	Median
Name	EyePoint	Ocular T.	Regenero.	Kodiak S.	Apellis .	Tarsus P.
Rev Chg LTM	-7.4%	-9.2%	2.9%	-	42.1%	182.4%	2.9%
Rev Chg 3Y Avg	0.1%	4.4%	1.4%	-	115.2%	324.5%	4.4%
Rev Chg Q	-90.8%	-5.7%	0.9%	-	133.0%	146.7%	0.9%
QoQ Delta Rev Chg LTM	-18.4%	-1.6%	0.2%	-	34.7%	23.9%	0.2%
Op Mgn LTM	-515.7%	-449.7%	26.7%	-	7.9%	-23.9%	-23.9%
Op Mgn 3Y Avg	-321.3%	-273.7%	30.0%	-	-80.7%	-308.0%	-273.7%
QoQ Delta Op Mgn LTM	-151.4%	-47.1%	-0.9%	-	33.1%	9.3%	-0.9%
CFO/Rev LTM	-498.1%	-340.7%	35.6%	-	7.8%	-14.7%	-14.7%
CFO/Rev 3Y Avg	-239.1%	-214.8%	35.4%	-	-84.9%	-237.2%	-214.8%
FCF/Rev LTM	-504.5%	-357.5%	27.2%	-	7.7%	-17.1%	-17.1%
FCF/Rev 3Y Avg	-247.0%	-225.7%	28.2%	-	-85.1%	-251.4%	-225.7%

Valuation

	EYPT	OCUL	REGN	KOD	APLS	TARS	Median
Name	EyePoint	Ocular T.	Regenero.	Kodiak S.	Apellis .	Tarsus P.
Mkt Cap	1.3	2.4	80.7	1.5	3.2	3.5	2.8
P/S	31.2	42.7	5.7	-	3.2	9.5	9.5
P/EBIT	-6.5	-10.0	15.6	-7.1	35.0	-48.0	-6.8
P/E	-6.4	-9.5	17.6	-7.0	71.4	-43.0	-6.7
P/CFO	-6.3	-12.5	15.9	-11.9	40.7	-64.7	-9.1
Total Yield	-15.6%	-10.5%	6.0%	-14.4%	1.4%	-2.3%	-6.4%
Dividend Yield	0.0%	0.0%	0.3%	0.0%	0.0%	0.0%	0.0%
FCF Yield 3Y Avg	-15.2%	-15.5%	4.9%	-110.0%	-5.7%	-9.3%	-12.2%
D/E	0.0	0.0	0.0	0.0	0.1	0.0	0.0
Net D/E	-0.1	-0.1	-0.1	-0.0	-0.0	-0.1	-0.1

Returns

	EYPT	OCUL	REGN	KOD	APLS	TARS	Median
Name	EyePoint	Ocular T.	Regenero.	Kodiak S.	Apellis .	Tarsus P.
1M Rtn	37.8%	5.9%	3.1%	37.7%	29.5%	2.9%	17.7%
3M Rtn	41.1%	6.2%	31.0%	90.6%	8.1%	47.4%	36.0%
6M Rtn	127.7%	54.8%	52.7%	688.2%	44.2%	101.9%	78.4%
12M Rtn	165.5%	52.5%	11.7%	230.8%	-23.5%	54.9%	53.7%
3Y Rtn	552.2%	385.4%	7.8%	307.0%	-50.1%	465.0%	346.2%
1M Excs Rtn	33.0%	5.4%	0.6%	40.8%	24.8%	1.3%	15.1%
3M Excs Rtn	37.4%	2.5%	34.1%	105.2%	6.2%	44.0%	35.8%
6M Excs Rtn	92.4%	29.7%	36.7%	679.6%	23.6%	85.1%	60.9%
12M Excs Rtn	136.2%	36.4%	-7.5%	209.8%	-42.5%	38.4%	37.4%
3Y Excs Rtn	526.8%	291.3%	-69.4%	230.4%	-128.1%	378.5%	260.9%

Comparison Analyses

	Title
0	EyePoint Pharmaceuticals vs. Sportsman's Warehouse: With Return Forecast Of 19%, Sportsman's Warehouse Is A Better Bet
1	EyePoint Pharmaceuticals vs. Marine Products: With Return Forecast Of 15%, Marine Products Is A Better Bet
2	EyePoint Pharmaceuticals vs. Quotient Technology: With Return Forecast Of 52%, Quotient Technology Is A Better Bet
3	EyePoint Pharmaceuticals vs. 1-800-FLOWERS.COM: Neither Seems Like A Good Bet
4	EyePoint Pharmaceuticals vs. Senseonics Holdings: With Return Forecast Of 4,474%, Senseonics Holdings Is A Better Bet
5	EyePoint Pharmaceuticals vs. LightPath Technologies: With Return Forecast Of 1.7%, EyePoint Pharmaceuticals Is A Better Bet
6	EyePoint Pharmaceuticals vs. Aehr Test Systems: With Return Forecast Of 19%, Aehr Test Systems Is A Better Bet
7	EyePoint Pharmaceuticals vs. ChemoCentryx: With Return Forecast Of 72%, ChemoCentryx Is A Better Bet

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for More

					Post-Approval Fwd Returns
FDA App #	Brand Name	Generic Name	Dosage Form	FDA Approval	3M Rtn	6M Rtn	1Y Rtn	2Y Rtn	Total Rtn
NDA208912	DEXYCU KIT	dexamethasone	suspension	2092018	93.3%	111.5%	129.8%	78.8%	81.2%

	Post-Approval Fwd Returns
NDA208912	DEXYCU KIT	dexamethasone	suspension	2092018	93.3%	111.5%	129.8%	78.8%	81.2%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	11/6/2025	3/6/2025	3/8/2024	3/10/2023	3/14/2022	3/12/2021	3/16/2020
Key Financials
Total Revenue	42	43	46	41	37	34	20
EBITDA	-201	-129	-69	-97	-50	-35	-48
Operating Income	-218	-146	-75	-79	-55	-37	-48
Net Income	-206	-131	-71	-102	-58	-45	-57
EPS	-2.99	-2.32	-1.82	-2.74	-2.03	-3.54	-5.44
Growth Rates
Total Revenue Growth	-7.4%	-6.0%	11.1%	12.1%	7.3%	69.1%	595.5%
EBITDA Growth	-77.3%	-87.3%	28.6%	-92.7%	-41.3%	26.1%	-15.0%
Operating Income Growth	-86.7%	-94.3%	4.9%	-42.8%	-48.2%	22.1%	-94.9%
Net Income Growth	-98.7%	-84.9%	30.8%	-75.0%	-28.7%	20.1%	-27.0%
Margins
EBITDA Margin	-475.1%	-298.6%	-149.9%	-233.4%	-135.8%	-103.1%	-235.8%
Operating Income Margin	-515.7%	-337.1%	-163.1%	-190.7%	-149.6%	-108.3%	-235.0%
Net Income Margin	-486.0%	-302.4%	-153.8%	-247.0%	-158.1%	-131.8%	-278.9%
Cash & Debt
Total Cash	204	371	331	145	212	45	22
Total Debt	21	22	5	46	39	41	50
Net Debt / (Cash)	-183	-349	-326	-99	-172	-4	28
Cash Flows
Net Cash from Operations	-211	-126	2	-65	-50	-14	-57
Free Cash from Operations	-214	-130	-2	-67	-50	-15	-57
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022
Filing Date	11/6/2025	8/7/2025	5/8/2025	3/6/2025	11/7/2024	8/8/2024	5/9/2024	3/8/2024	11/3/2023	8/4/2023	5/4/2023	3/10/2023
Key Financials Quarterly
Total Revenue	1	5	24	12	11	9	12	14	15	9	8	11
Ebitda	-61	-62	-48	-30	-32	-34	-33	-14	-12	-22	-20	-42
Operating Income	-62	-62	-49	-45	-33	-35	-33	-16	-14	-23	-22	-23
Net Income	-60	-59	-45	-41	-29	-31	-29	-14	-13	-23	-21	-43
EPS	-0.85	-0.85	-0.65	-0.64	-0.54	-0.58	-0.55	-0.32	-0.33	-0.61	-0.56	-1.16
Key Financials TTM
Total Revenue TTM	42	52	56	43	46	50	50	46	43	37	40	41
Ebitda TTM	-201	-172	-145	-129	-113	-94	-82	-69	-97	-102	-98	-97
Operating Income TTM	-218	-189	-161	-146	-117	-99	-87	-75	-82	-86	-82	-79
Net Income TTM	-206	-175	-147	-131	-104	-87	-79	-71	-100	-106	-102	-102
Growth Rates Quarterly
Total Revenue Growth	-90.8%	-43.7%	109.3%	-17.4%	-30.8%	4.1%	52.1%	33.2%	51.8%	-21.3%	-17.3%	-8.8%
EBITDA Growth	-90.0%	-80.5%	-46.4%	-113.5%	-158.8%	-52.9%	-63.1%	67.2%	26.7%	-23.2%	-6.1%	-144.1%
Operating Income Growth	-89.4%	-80.1%	-46.6%	-176.6%	-127.4%	-51.8%	-54.6%	29.0%	21.7%	-18.4%	-17.9%	-27.6%
Net Income Growth	-103.4%	-92.8%	-54.3%	-193.6%	-132.8%	-34.5%	-38.4%	67.6%	31.5%	-18.1%	-0.9%	-123.6%
Margins Quarterly
EBITDA Margin	-6361.2%	-1156.7%	-197.7%	-256.2%	-307.3%	-360.7%	-282.6%	-99.1%	-82.2%	-245.5%	-263.5%	-401.9%
Operating Income Margin	-6420.8%	-1166.8%	-199.7%	-390.4%	-311.2%	-364.5%	-285.2%	-116.6%	-94.7%	-250.0%	-280.5%	-218.7%
Net Income Margin	-6183.4%	-1114.3%	-184.8%	-357.3%	-279.0%	-325.3%	-250.6%	-100.5%	-83.0%	-251.7%	-275.5%	-412.5%
Cash & Debt
Total Cash	204	256	318	371	254	280	299	331	136	143	122	145
Total Debt	21	22	24	22	22	23	5	5	6	6	40	46
Net Debt / (Cash)	-183	-234	-294	-349	-232	-257	-295	-326	-130	-136	-82	-99
Cash Flows Quarterly
FCF from Operations	-59	-63	-53	-36	-39	-20	-31	-23	-15	57	-17	-13
Cash Flows TTM
FCF from Operations TTM	-211	-191	-148	-126	-113	-90	-12	2	12	14	-62	-65
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-23.5%	-25.1%	-21.2%	-21.0%	-16.0%	-17.9%	-18.3%	-9.6%	-8.8%	-14.3%	-12.5%	-13.8%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-20.7%	-19.1%	-17.5%	-17.0%	-14.3%	-12.7%	-12.0%	-11.0%	-12.4%	-13.5%	-11.9%	-11.8%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Business of developing and commercializing innovative ophthalmic products for the treatment of eye	46
Dexamethasone intraocular suspension (DEXYCU)		12	18	7	5
Fluocinolone acetonide intravitreal implant (YUTIQ)		28	17	14	12
License and collaboration agreements		0	1	12	1
Royalty income		1	1	2	2
Total	46	41	37	34	20

Net Income by Segment

$ Mil	2024	2023	2022	2021	2020
Business of developing and commercializing innovative ophthalmic products for the treatment of eye	-71
Total	-71

Price Behavior

Price Behavior

Market Price	$18.85
Market Cap ($ Bil)	1.3
First Trading Date	06/26/2008
Distance from 52W High	0.0%
	50 Days	200 Days
DMA Price	$13.78	$10.31
DMA Trend	up	up
Distance from DMA	36.7%	82.8%
	3M	1YR
Volatility	75.0%	78.2%
Downside Capture	11.21	71.37
Upside Capture	177.53	157.06
Correlation (SPY)	12.2%	27.6%

EYPT Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	0.44	0.47	0.27	0.89	1.12	1.24
Up Beta	1.96	2.17	2.04	2.11	1.26	0.76
Down Beta	4.57	0.82	1.41	0.68	0.95	1.29
Up Capture	117%	1%	11%	163%	161%	877%
Bmk +ve Days	12	25	38	73	141	426
Stock +ve Days	14	25	40	73	134	366
Down Capture	-161%	-30%	-169%	-53%	96%	108%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	5	16	22	51	113	375

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

		Comparison of EYPT With Other Asset Classes (Last 1Y)
	EYPT	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	135.0%	13.6%	14.7%	67.3%	6.8%	-0.5%	-16.6%
Annualized Volatility	78.1%	17.3%	19.7%	19.3%	15.2%	17.6%	35.4%
Sharpe Ratio	1.42	0.57	0.57	2.54	0.23	-0.18	-0.25
Correlation With Other Assets		25.9%	28.7%	1.5%	5.9%	19.4%	17.4%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of EYPT With Other Asset Classes (Last 5Y)
	EYPT	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	33.0%	8.7%	15.0%	18.9%	11.8%	5.1%	35.8%
Annualized Volatility	120.8%	14.5%	17.1%	15.5%	18.7%	18.9%	48.9%
Sharpe Ratio	0.67	0.42	0.71	0.98	0.51	0.18	0.63
Correlation With Other Assets		15.2%	16.3%	-1.2%	1.2%	15.5%	12.6%

Based On 10-Year Data

		Comparison of EYPT With Other Asset Classes (Last 10Y)
	EYPT	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-6.0%	10.0%	14.9%	14.9%	6.7%	5.5%	69.9%
Annualized Volatility	100.8%	16.7%	18.0%	14.8%	17.6%	20.8%	55.8%
Sharpe Ratio	0.33	0.50	0.71	0.84	0.30	0.23	0.90
Correlation With Other Assets		20.7%	22.1%	-1.6%	6.4%	19.0%	9.9%

Short Interest

Short Interest: As Of Date	11282025
Short Interest: Shares Quantity	7,881,028
Short Interest: % Change Since 11152025	-8.7%
Average Daily Volume	1,112,401
Days-to-Cover Short Interest	7.08
Basic Shares Quantity	70,168,000
Short % of Basic Shares	11.2%

Returns Analyses

	Title
0	Would You Still Hold EyePoint Stock If It Fell 30%?
1	EyePoint Pharmaceuticals Stock Return Comparison
2	[10/13/2021] EyePoint Pharmaceuticals (EYPT) Stock Price Forecast: AI Forecasts EYPT Stock Price To Be Around $12.01 In A Month (Up 11%)
3	EyePoint Pharmaceuticals Total Shareholder Return (TSR): -71.4% in 2022 and -39.1% 3-yr returns (below peer average)

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
11/5/2025	-11.1%	-6.0%	43.2%
8/6/2025	-2.8%	-1.3%	9.1%
5/7/2025	-2.6%	-5.4%	32.0%
1/13/2025	-7.1%	-10.3%	-24.7%
10/28/2024	27.6%	26.9%	-2.8%
8/7/2024	-4.1%	-13.0%	-10.6%
5/8/2024	-2.6%	4.9%	-21.9%
1/10/2024	-5.8%	1.9%	35.6%
...
SUMMARY STATS
# Positive	8	10	11
# Negative	13	11	10
Median Positive	10.1%	18.2%	27.3%
Median Negative	-5.0%	-6.0%	-11.8%
Max Positive	27.6%	42.3%	43.2%
Max Negative	-17.2%	-13.0%	-41.0%

	Forward Returns
11/5/2025	-11.1%	-6.0%	43.2%
8/6/2025	-2.8%	-1.3%	9.1%
5/7/2025	-2.6%	-5.4%	32.0%
1/13/2025	-7.1%	-10.3%	-24.7%
10/28/2024	27.6%	26.9%	-2.8%
8/7/2024	-4.1%	-13.0%	-10.6%
5/8/2024	-2.6%	4.9%	-21.9%
1/10/2024	-5.8%	1.9%	35.6%
11/1/2023	20.3%	27.1%	3.8%
8/2/2023	0.7%	-2.6%	-12.9%
3/2/2023	-8.8%	-10.9%	0.9%
11/2/2022	-5.4%	-0.9%	-41.0%
7/18/2022	5.0%	4.9%	10.5%
3/3/2022	15.3%	42.3%	23.9%
11/3/2021	2.5%	29.2%	27.3%
8/4/2021	1.8%	15.9%	28.4%
3/4/2021	-17.2%	-9.9%	-6.8%
11/5/2020	-2.4%	3.9%	29.1%
8/5/2020	-5.0%	-10.0%	-31.5%
5/6/2020	-2.4%	-3.0%	-9.2%
1/23/2020	23.6%	20.5%	-9.9%
SUMMARY STATS
# Positive	8	10	11
# Negative	13	11	10
Median Positive	10.1%	18.2%	27.3%
Median Negative	-5.0%	-6.0%	-11.8%
Max Positive	27.6%	42.3%	43.2%
Max Negative	-17.2%	-13.0%	-41.0%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11062025	10-Q 9/30/2025
6302025	8072025	10-Q 6/30/2025
3312025	5082025	10-Q 3/31/2025
12312024	3062025	10-K 12/31/2024
9302024	11072024	10-Q 9/30/2024
6302024	8082024	10-Q 6/30/2024
3312024	5092024	10-Q 3/31/2024
12312023	3082024	10-K 12/31/2023
9302023	11032023	10-Q 9/30/2023
6302023	8042023	10-Q 6/30/2023
3312023	5042023	10-Q 3/31/2023
12312022	3102023	10-K 12/31/2022
9302022	11042022	10-Q 9/30/2022
6302022	8052022	10-Q 6/30/2022
3312022	5062022	10-Q 3/31/2022
12312021	3142022	10-K 12/31/2021

Insider Activity

Expand for Morenull

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

EyePoint (EYPT)

Market Price (12/23/2025): $18.85 | Market Cap: $1.3 BilSector: Health Care | Industry: Biotechnology

EyePoint (EYPT)

Market Price (12/23/2025): $18.85Market Cap: $1.3 BilSector: Health CareIndustry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

EYPT Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About EyePoint (EYPT)

EyePoint Pharmaceuticals' Addressable Markets

YUTIQ® (fluocinolone acetonide intravitreal implant)

DEXYCU® (dexamethasone intraocular suspension)

EYP-1901 (DURAVYU™)

Expected Drivers of Future Revenue Growth for EyePoint (EYPT)

Interactive Breakdown

Better Bets than EyePoint (EYPT)

INDUSTRY: Biotechnology

Higher Rev Chg 3Y Avg | Lower P/S (Values for EYPT: 0.1% | 31.2x)

Higher Rev Chg LTM (Value for EYPT: -7.4%)

Higher Rev Chg 3Y Avg (Value for EYPT: 0.1%)

Higher Op Mgn LTM (Value for EYPT: -515.7%)

Higher CFO/Rev LTM (Value for EYPT: -498.1%)

Higher FCF/Rev LTM (Value for EYPT: -504.5%)

Higher Total Yield (Value for EYPT: -15.6%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for EYPT: 0.1% | 31.2x)

Higher Rev Chg LTM (Value for EYPT: -7.4%)

Higher Rev Chg 3Y Avg (Value for EYPT: 0.1%)

Higher Op Mgn LTM (Value for EYPT: -515.7%)

Higher CFO/Rev LTM (Value for EYPT: -498.1%)

Higher FCF/Rev LTM (Value for EYPT: -504.5%)

Higher Total Yield (Value for EYPT: -15.6%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for EYPT: 0.1% | 31.2x)

Higher Rev Chg LTM (Value for EYPT: -7.4%)

Higher Rev Chg 3Y Avg (Value for EYPT: 0.1%)

Higher Op Mgn LTM (Value for EYPT: -515.7%)

Higher CFO/Rev LTM (Value for EYPT: -498.1%)

Higher FCF/Rev LTM (Value for EYPT: -504.5%)

Higher Total Yield (Value for EYPT: -15.6%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for EyePoint

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Market Price (12/23/2025): $18.85 | Market Cap: $1.3 Bil
Sector: Health Care | Industry: Biotechnology

Market Price (12/23/2025): $18.85
Market Cap: $1.3 Bil
Sector: Health Care
Industry: Biotechnology